We are live on ! Find out more
TTPH

Tetraphase Pharmaceuticals
TTPH

Delisted

TTPH was delisted on the 28th of July, 2020.

90 hedge funds and large institutions have $77.5M invested in Tetraphase Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 28 increasing their positions, 27 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more call options, than puts

Call options by funds: $789K | Put options by funds: $595K

4% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 27

2.56% less ownership

Funds ownership: 44.6% → 42.04% (-2.6%)

4% less funds holding

Funds holding: 94 → 90 (-4)

20% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 15

29% less capital inflows, than outflows

Capital inflows: $9.5M | Capital outflows: $13.5M

Holders
90
Holders Change
-4
Holders Change %
-4.26%
% of All Funds
2.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
28
Reduced
27
Closed
15
Calls
$789​K
Puts
$595​K
Net Calls
+$194​K
Net Calls Change
-⁠$187​K

TTPH Hedge Fund Activity: Q2 2018 in Review

90 of the 4,387 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals (TTPH) for Q2 2018, worth a combined $77.5M — up 9.6% from $70.7M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of TTPH and 12 opened new positions — a net loss of 3 holders — while 27 trimmed existing stakes and 28 added.

The largest buyer was JP Morgan Chase, adding an estimated $1.71M. The largest seller was Man Group, cutting an estimated $3.31M.

  • 90 institutional investors held Tetraphase Pharmaceuticals (TTPH) as of Q2 2018, down from 94 in Q1 2018.
  • Funds reported $77.5M of Tetraphase Pharmaceuticals stock for Q2 2018, up 9.6% quarter-over-quarter.
  • 12 funds opened new Tetraphase Pharmaceuticals positions in Q2 2018 and 15 closed out, a net change of -3 holders.
  • The largest Tetraphase Pharmaceuticals buyer in Q2 2018 was JP Morgan Chase, an estimated $1.71M added.
  • The largest Tetraphase Pharmaceuticals seller in Q2 2018 was Man Group, an estimated $3.31M sold.

Based on aggregated 13F filings for Q2 2018.